

Drug Policy:

Koselugo™ (selumetinib)

POLICY NUMBER UM ONC_1396	SUBJECT Koselugo™ (selumetinib)	DEPT/PROGRAM UM Dept	PAGE 1 OF 2
DATES COMMITTEE REVIEWED 05/13/20, 11/11/20	APPROVAL DATE November 11, 2020	EFFECTIVE DATE November 30, 2020	COMMITTEE APPROVAL DATES (latest version listed last) 05/13/20, 11/11/20
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee	
URAC STANDARDS HUM 1	NCQA STANDARDS UM 2	ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS	APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Koselugo (selumetinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)

3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the [Preferred Drug Guidelines](#) shall follow [NCH L1 Pathways](#) when applicable, otherwise shall follow NCH drug policies **AND**
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision **AND**
5. When available, generic alternatives are preferred over brand-name drugs.

B. Plexiform Neurofibromas (PN)

1. Koselugo (selumetinib) will be used as a single agent in children 2 years of age and older with all of the following conditions:
 - a. Inoperable plexiform neurofibromas (PN)
 - b. Positive neurofibromatosis type 1 (NF1) mutation
 - c. The member is symptomatic (e.g. signs of hypertension, hydrocephalus, seizures, macrocephaly, skeletal changes, worsening visual changes, or cognitive and learning deficits).

III. EXCLUSION CRITERIA

- A. Disease progression while receiving Koselugo (selumetinib).
- B. Dosing exceeds single dose limit of Koselugo (selumetinib) 50 mg.
- C. Treatment exceeds the maximum limit of 90 (10 mg) or 120 (25 mg) tablets/month.
- D. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Koselugo PI prescribing information. AstraZeneca Pharmaceuticals LP. Wilmington, DE 2020.
- B. Clinical Pharmacology Elsevier Gold Standard. 2020.
- C. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2020.
- D. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2020.
- E. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2020.